Role of Kupffer cells in host defense and liver disease.

Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev (2008) 10.28

Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology (2010) 3.52

Kupffer cell and interleukin-12-dependent loss of natural killer T cells in hepatosteatosis. Hepatology (2010) 2.48

Toll-like receptors as targets in chronic liver diseases. Gut (2009) 2.29

Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement. J Virol (2008) 1.93

Immune surveillance by the liver. Nat Immunol (2013) 1.79

NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications. Gut Liver (2012) 1.70

Functional role of monocytes and macrophages for the inflammatory response in acute liver injury. Front Physiol (2012) 1.49

Contrasting responses of Kupffer cells and inflammatory mononuclear phagocytes to biliary obstruction in a mouse model of cholestatic liver injury. Liver Int (2012) 1.45

Advances and future challenges in adenoviral vector pharmacology and targeting. Curr Gene Ther (2011) 1.42

Role of toll-like receptors and their downstream molecules in the development of nonalcoholic Fatty liver disease. Gastroenterol Res Pract (2011) 1.37

Neutrophils contribute to development of a protective immune response during onset of infection with Leishmania donovani. Infect Immun (2007) 1.36

Microglia and monocyte-derived macrophages: functionally distinct populations that act in concert in CNS plasticity and repair. Front Cell Neurosci (2013) 1.34

Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap Adv Gastroenterol (2011) 1.34

Dynamic imaging of experimental Leishmania donovani-induced hepatic granulomas detects Kupffer cell-restricted antigen presentation to antigen-specific CD8 T cells. PLoS Pathog (2010) 1.32

Microanatomy of the liver immune system. Semin Immunopathol (2009) 1.22

The effect of inflammatory cytokines in alcoholic liver disease. Mediators Inflamm (2013) 1.18

Advances in antifibrotic therapy. Expert Rev Gastroenterol Hepatol (2008) 1.17

Non-alcoholic fatty liver disease: The diagnosis and management. World J Hepatol (2015) 1.11

Innate immune cells in liver inflammation. Mediators Inflamm (2012) 1.11

Apoptosis and necrosis in the liver. Compr Physiol (2013) 1.05

Macrophages in hepatitis B and hepatitis C virus infections. J Virol (2008) 1.05

Early life activation of toll-like receptor 4 reprograms neural anti-inflammatory pathways. J Neurosci (2010) 1.03

Oxidative stress signaling underlying liver disease and hepatoprotective mechanisms. World J Hepatol (2009) 1.02

Arginine homeostasis and transport in the human pathogen Leishmania donovani. J Biol Chem (2009) 1.00

Dissecting the complement pathway in hepatic injury and regeneration with a novel protective strategy. J Exp Med (2014) 0.97

CcpA mediates proline auxotrophy and is required for Staphylococcus aureus pathogenesis. J Bacteriol (2010) 0.97

Inflammatory mediators and insulin resistance in obesity: role of nuclear receptor signaling in macrophages. Mediators Inflamm (2010) 0.97

Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update. World J Gastroenterol (2014) 0.97

Ricinus communis intoxications in human and veterinary medicine-a summary of real cases. Toxins (Basel) (2011) 0.96

N-3 PUFA supplementation triggers PPAR-α activation and PPAR-α/NF-κB interaction: anti-inflammatory implications in liver ischemia-reperfusion injury. PLoS One (2011) 0.96

Generation of a Kupffer cell-evading adenovirus for systemic and liver-directed gene transfer. Mol Ther (2011) 0.95

Carbon monoxide induces hypothermia tolerance in Kupffer cells and attenuates liver ischemia/reperfusion injury in rats. Liver Transpl (2011) 0.93

Augmented particle trapping and attenuated inflammation in the liver by protective vaccination against Plasmodium chabaudi malaria. Malar J (2009) 0.93

Liver-inherent immune system: its role in blood-stage malaria. Front Microbiol (2014) 0.93

New insights into the role of macrophages in adipose tissue inflammation and Fatty liver disease: modulation by endogenous omega-3 Fatty Acid-derived lipid mediators. Front Immunol (2011) 0.93

Role of innate immune response in non-alcoholic Fatty liver disease: metabolic complications and therapeutic tools. Front Immunol (2014) 0.92

Acute-on-Chronic Liver Failure. Clin Gastroenterol Hepatol (2015) 0.92

Bimodal role of Kupffer cells during colorectal cancer liver metastasis. Cancer Biol Ther (2013) 0.91

Gut bacteria drive Kupffer cell expansion via MAMP-mediated ICAM-1 induction on sinusoidal endothelium and influence preservation-reperfusion injury after orthotopic liver transplantation. Am J Pathol (2012) 0.90

Featured Article: Isolation, characterization, and cultivation of human hepatocytes and non-parenchymal liver cells. Exp Biol Med (Maywood) (2014) 0.89

Vitamin D deficiency in chronic liver disease. World J Hepatol (2014) 0.89

Therapeutic targeting of liver inflammation and fibrosis by nanomedicine. Hepatobiliary Surg Nutr (2014) 0.89

TNF-{alpha} plays a role in hepatocyte apoptosis in Niemann-Pick type C liver disease. J Lipid Res (2008) 0.89

Macrophage autophagy limits acute toxic liver injury in mice through down regulation of interleukin-1β. J Hepatol (2015) 0.88

Extrahepatic complications to cirrhosis and portal hypertension: haemodynamic and homeostatic aspects. World J Gastroenterol (2014) 0.88

Sinusoidal communication in liver fibrosis and regeneration. J Hepatol (2016) 0.88

Monocytes and macrophages as nanomedicinal targets for improved diagnosis and treatment of disease. Expert Rev Mol Diagn (2013) 0.88

Liver immunology and its role in inflammation and homeostasis. Cell Mol Immunol (2016) 0.88

The betaine/GABA transporter and betaine: roles in brain, kidney, and liver. Front Physiol (2014) 0.88

Bench-to-beside review: acute-on-chronic liver failure - linking the gut, liver and systemic circulation. Crit Care (2011) 0.87

Innate immune reactivity of the liver in rats fed a choline-deficient L-amino-acid-defined diet. World J Gastroenterol (2008) 0.86

Graptopetalum paraguayense ameliorates chemical-induced rat hepatic fibrosis in vivo and inactivates stellate cells and Kupffer cells in vitro. PLoS One (2013) 0.86

NK cells suppress experimental cholestatic liver injury by an interleukin-6-mediated, Kupffer cell-dependent mechanism. J Hepatol (2010) 0.86

Natural history of hepatic metastases from colorectal cancer--pathobiological pathways with clinical significance. World J Gastroenterol (2014) 0.86

Hydroxysafflor yellow A attenuates ischemia/reperfusion-induced liver injury by suppressing macrophage activation. Int J Clin Exp Pathol (2014) 0.86

Pharmacological Intervention in Hepatic Stellate Cell Activation and Hepatic Fibrosis. Front Pharmacol (2016) 0.86

A safety evaluation of DAS181, a sialidase fusion protein, in rodents. Toxicol Sci (2011) 0.85

Hepatocyte apoptotic bodies encasing nonstructural HCV proteins amplify hepatic stellate cell activation: implications for chronic hepatitis C. J Viral Hepat (2010) 0.85

Clinical and Pathophysiological Consequences of Alterations in the Microbiome in Cirrhosis. Am J Gastroenterol (2015) 0.85

Novel Action of Carotenoids on Non-Alcoholic Fatty Liver Disease: Macrophage Polarization and Liver Homeostasis. Nutrients (2016) 0.84

Long-term maintenance of a microfluidic 3D human liver sinusoid. Biotechnol Bioeng (2015) 0.83

Oval cell response is attenuated by depletion of liver resident macrophages in the 2-AAF/partial hepatectomy rat. PLoS One (2012) 0.83

Immune cells and metabolic dysfunction. Semin Immunopathol (2013) 0.83

The coagulation factor Xa/protease activated receptor-2 axis in the progression of liver fibrosis: a multifaceted paradigm. J Cell Mol Med (2009) 0.83

Novel therapy for liver regeneration by increasing the number of platelets. Surg Today (2012) 0.83

The engagement of selectins and their ligands in colorectal cancer liver metastases. J Cell Mol Med (2010) 0.82

Suppressor of cytokine signaling expression with increasing severity of murine hepatic ischemia-reperfusion injury. J Hepatol (2008) 0.82

Liver myofibroblasts up-regulate monocyte CD163 expression via PGE2 during hepatitis B induced liver failure. J Transl Med (2014) 0.82

Staging of liver fibrosis or cirrhosis: The role of hepatic venous pressure gradient measurement. World J Hepatol (2015) 0.82

Acute-on-chronic liver failure: Pathogenesis, prognostic factors and management. World J Gastroenterol (2015) 0.82

Grapefruit-derived nanovectors deliver miR-18a for treatment of liver metastasis of colon cancer by induction of M1 macrophages. Oncotarget (2016) 0.82

The mitochondria-targeted antioxidant MitoQ attenuates liver fibrosis in mice. Int J Physiol Pathophysiol Pharmacol (2016) 0.82

Prolonged hepatomegaly in mice that cannot inactivate bacterial endotoxin. Hepatology (2011) 0.81

Emergence and Utility of Nonspherical Particles in Biomedicine. Ind Eng Chem Res (2015) 0.81

Nuclear receptors: mediators and modifiers of inflammation-induced cholestasis. Front Biosci (Landmark Ed) (2009) 0.81

Microengineered cell and tissue systems for drug screening and toxicology applications: Evolution of in-vitro liver technologies. Technology (Singap World Sci) (2015) 0.81

Surface antigens contribute differently to the pathophysiological features in serotype K1 and K2 Klebsiella pneumoniae strains isolated from liver abscesses. Gut Pathog (2016) 0.81

The effects of either resveratrol or exercise on macrophage infiltration and switching from M1 to M2 in high fat diet mice. J Exerc Nutrition Biochem (2015) 0.81

Sorting Out Pandora's Box: Discerning the Dynamic Roles of Liver Microenvironment in Oncolytic Virus Therapy for Hepatocellular Carcinoma. Front Oncol (2014) 0.80

Role of the exogenous HCV core protein in the interaction of human hepatocyte proliferation and macrophage sub-populations. PLoS One (2014) 0.80

Characterization of the liver-macrophages isolated from a mixed primary culture of neonatal swine hepatocytes. Results Immunol (2014) 0.80

Atherofibrosis - a unique and common process of the disease pathogenesis of atherosclerosis and fibrosis - lessons for biomarker development. Am J Transl Res (2013) 0.79

Decreased cystathionine-γ-lyase (CSE) activity in livers of type 1 diabetic rats and peripheral blood mononuclear cells (PBMC) of type 1 diabetic patients. J Biol Chem (2014) 0.79

MAIT cells: new guardians of the liver. Clin Transl Immunology (2016) 0.79

Liver myofibroblasts regulate the phenotype and function of monocytes through soluble factors in cirrhosis. Exp Ther Med (2012) 0.79

Signal transduction of platelet-induced liver regeneration and decrease of liver fibrosis. Int J Mol Sci (2014) 0.79

A disintegrin and metalloproteinase 17 regulates TNF and TNFR1 levels in inflammation and liver regeneration in mice. Am J Physiol Gastrointest Liver Physiol (2013) 0.78

Chinese medicine CGA formula ameliorates DMN-induced liver fibrosis in rats via inhibiting MMP2/9, TIMP1/2 and the TGF-β/Smad signaling pathways. Acta Pharmacol Sin (2016) 0.78

Pathological Lesions and Inducible Nitric Oxide Synthase Expressions in the Liver of Mice Experimentally Infected with Clonorchis sinensis. Korean J Parasitol (2015) 0.78

Organ-specific testosterone-insensitive response of miRNA expression of C57BL/6 mice to Plasmodium chabaudi malaria. Parasitol Res (2012) 0.78

Technical advance: liposomal alendronate depletes monocytes and macrophages in the nonhuman primate model of human disease. J Leukoc Biol (2014) 0.78

C(6)-ceramide enhances phagocytic activity of Kupffer cells through the production of endogenous ceramides. Mol Cells (2011) 0.78

Enhanced performance of macrophage-encapsulated nanoparticle albumin-bound-paclitaxel in hypo-perfused cancer lesions. Nanoscale (2016) 0.78

Zirconium tetraazamacrocycle complexes display extraordinary stability and provide a new strategy for zirconium-89-based radiopharmaceutical development. Chem Sci (2016) 0.78

Ischemia/Reperfusion. Compr Physiol (2016) 0.78

The innate immune receptor Dectin-2 mediates the phagocytosis of cancer cells by Kupffer cells for the suppression of liver metastasis. Proc Natl Acad Sci U S A (2016) 0.77

HIV protease inhibitors in gut barrier dysfunction and liver injury. Curr Opin Pharmacol (2014) 0.77

The renin angiotensin system regulates Kupffer cells in colorectal liver metastases. Cancer Biol Ther (2013) 0.77

Protective Effects of Dracocephalum heterophyllum in ConA-Induced Acute Hepatitis. Mediators Inflamm (2016) 0.77

TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut (2010) 2.24

Suramin inhibits death receptor-induced apoptosis in vitro and fulminant apoptotic liver damage in mice. Nat Med (2004) 1.54

Atrial natriuretic peptide preconditioning protects against hepatic preservation injury by attenuating necrotic and apoptotic cell death. J Hepatol (2003) 1.45

Hepatic arterial buffer response in patients with advanced cirrhosis. Hepatology (2002) 1.21

Inhibition of c-Jun-N-terminal-kinase sensitizes tumor cells to CD95-induced apoptosis and induces G2/M cell cycle arrest. Cancer Res (2005) 1.11

Glutathione protects the rat liver against reperfusion injury after prolonged warm ischemia. Ann Surg (2004) 1.08

The impact of acute kidney injury in cirrhosis: does definition matter? Gut (2013) 1.07

Induction of cellular resistance against Kupffer cell-derived oxidant stress: a novel concept of hepatoprotection by ischemic preconditioning. Hepatology (2003) 1.00

Intravenous administration of glutathione protects parenchymal and non-parenchymal liver cells against reperfusion injury following rat liver transplantation. World J Gastroenterol (2004) 1.00

Electrophoretic analysis of the mitochondrial outer membrane rupture induced by permeability transition. Anal Chem (2008) 0.99

Characterization of organic anion transporter regulation, glutathione metabolism and bile formation in the obese Zucker rat. J Hepatol (2005) 0.95

Kupffer cell activation in normal and fibrotic livers increases portal pressure via thromboxane A(2). J Hepatol (2007) 0.95

Rapid development of esophageal squamous cell carcinoma after liver transplantation for alcohol-induced cirrhosis. Transpl Int (2003) 0.94

Expression, cellular distribution, and prognostic relevance of TRAIL receptors in hepatocellular carcinoma. Clin Cancer Res (2010) 0.93

Protein kinase A dependent signalling mediates anti-apoptotic effects of the atrial natriuretic peptide in ischemic livers. J Hepatol (2004) 0.92

Amiloride reduces portal hypertension in rat liver cirrhosis. Gut (2010) 0.92

The atrial natriuretic peptide and cGMP: novel activators of the heat shock response in rat livers. Hepatology (2002) 0.89

Treatment of Crigler-Najjar type 1 disease: relevance of early liver transplantation. J Pediatr Surg (2003) 0.89

Psychiatric and psychosocial outcome of orthotopic liver transplantation. Psychother Psychosom (2002) 0.88

P60-c-src suppresses apoptosis through inhibition of caspase 8 activation in hepatoma cells, but not in primary hepatocytes. J Hepatol (2006) 0.87

Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: a safe and effective therapy? Gastroenterology (2005) 0.87

Intraperitoneal LPS amplifies portal hypertension in rat liver fibrosis. Lab Invest (2010) 0.87

Portal pressure regulation following Kupffer cell activation: control of prostaglandin production by heme oxygenases. Digestion (2013) 0.85

Benefit of TIPS for patients with refractory or recidivant ascites: serum bilirubin may make the difference. Hepatology (2005) 0.85

Hepatocyte cytoskeleton during ischemia and reperfusion--influence of ANP-mediated p38 MAPK activation. World J Gastroenterol (2005) 0.83

Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to i.v. bolus administration. Gastroenterology (2009) 0.83

Stimulation of p38 MAPK by hormonal preconditioning with atrial natriuretic peptide. World J Gastroenterol (2002) 0.82

Ischaemic and pharmacological preconditionings protect liver via adenosine and redox status following hepatic ischaemia/reperfusion in rats. Clin Sci (Lond) (2008) 0.82

Microsatellite instability, KRAS mutations and cellular distribution of TRAIL-receptors in early stage colorectal cancer. PLoS One (2012) 0.82

Kupffer-cell specific induction of heme oxygenase 1 (hsp32) by the atrial natriuretic peptide--role of cGMP. J Hepatol (2003) 0.82

The atrial natriuretic peptide as a regulator of Kupffer cell functions. Shock (2002) 0.82

Glutathione treatment protects the rat liver against injury after warm ischemia and Kupffer cell activation. Digestion (2002) 0.81

Improved quality of life in patients with refractory or recidivant ascites after insertion of transjugular intrahepatic portosystemic shunts. Digestion (2002) 0.80

Infection as a Trigger for Portal Hypertension. Dig Dis (2015) 0.80

Treatment with the leukotriene inhibitor montelukast for 10 days attenuates portal hypertension in rat liver cirrhosis. Hepatology (2010) 0.79

ANP-induced decrease of iron regulatory protein activity is independent of HO-1 induction. Am J Physiol Gastrointest Liver Physiol (2004) 0.78

Functional relevance of the cannabinoid receptor 2 - heme oxygenase pathway: a novel target for the attenuation of portal hypertension. Life Sci (2013) 0.78

Kupffer cell activation by hydrogen peroxide: a new mechanism of portal pressure increase. Shock (2010) 0.77

Drug-Induced Liver Injury and Individual Cell Models. Dig Dis (2015) 0.77

Insufficient sensitivity of reagent strips for spontaneous bacterial peritonitis. Hepatology (2007) 0.77

PI 3-kinase pathway is responsible for antiapoptotic effects of atrial natriuretic peptide in rat liver transplantation. World J Gastroenterol (2006) 0.76

High age and low sodium urine concentration are associated with poor survival in patients with hepatorenal syndrome. Ann Hepatol (2013) 0.76

Antioxidant effects of xanthohumol and functional impact on hepatic ischemia-reperfusion injury. J Nat Prod (2009) 0.76

Liver dysfunction in patients with IBD under immunosuppressive treatment: do we need to fear? Gut (2010) 0.76

Human monocyte-derived cells with individual hepatocyte characteristics: a novel tool for personalized in vitro studies. Lab Invest (2012) 0.75

Progress in treatment of massive ascites and hepatorenal syndrome. World J Gastroenterol (2006) 0.75

Renal failure in cirrhosis. N Engl J Med (2010) 0.75

Role of cholesterol determination in ascitic fluid analysis. Hepatology (2009) 0.75

Reliable Quantification of the Potential for Equations Based on Spot Urine Samples to Estimate Population Salt Intake: Protocol for a Systematic Review and Meta-Analysis. JMIR Res Protoc (2016) 0.75

Short-term treatment with mycophenolic acid increases bile flow in continuously perfused and cold-preserved rat livers and does not affect hepatic ischemia-reperfusion injury. Transpl Int (2002) 0.75

In-vivo quantification of hepatic 11beta-hydroxysteroid dehydrogenase type I activity--a preliminary study. Clin Biochem (2002) 0.75

The Challenge of Drug-Induced Liver Injury (DILI) / Challenges and Management of Liver Cirrhosis. Preface. Dig Dis (2015) 0.75

[The history and status of transplantation medicine]. Pharm Unserer Zeit (2005) 0.75

Daily profile of circulating C-type natriuretic peptide in pre-ascitic cirrhosis and in normal subjects: relationship with renal function. Scand J Gastroenterol (2007) 0.75

Role of cysteinyl-leukotrienes for portal pressure regulation and liver damage in cholestatic rat livers. Lab Invest (2013) 0.75